humulene and Infant--Premature--Diseases

humulene has been researched along with Infant--Premature--Diseases* in 2 studies

Trials

1 trial(s) available for humulene and Infant--Premature--Diseases

Article	Year
Risk of neonatal and childhood morbidity among preterm infants exposed to marijuana. The journal of maternal-fetal & neonatal medicine : the official journal of the European Association of Perinatal Medicine, the Federation of Asia and Oceania Perinatal Societies, the International Society of Perinatal Obstetricians, 2017, Volume: 30, Issue:24 Limited data exist regarding the neonatal and neurodevelopmental outcomes of infants exposed to marijuana (MJ) in-utero, particularly among preterm infants. We hypothesized that MJ-exposed preterm infants would have worse neonatal and childhood developmental outcomes compared to MJ-unexposed infants.. Secondary analysis of multicenter randomized-controlled trial of antenatal magnesium sulfate for the prevention of cerebral palsy was conducted. Singleton nonanomalous infants delivered <35 weeks exposed to MJ in-utero were compared to MJ-unexposed. Primary neonatal outcome was death, grade 3/4 intraventricular hemorrhage, periventricular leukomalacia, bronchopulmonary dysplasia, and/or stage II/III necrotizing enterocolitis before discharge. Primary childhood outcome was death, moderate/severe cerebral palsy, or/and Bayley II Scales <70 at age 2. Backward-stepwise regression used to estimate odds of primary outcomes.. 1867 infants met inclusion criteria; 135(7.2%) were MJ-exposed. There were no differences in neonatal (20% vs. 26%, p = 0.14) or childhood (26% vs. 21%, p = 0.21) outcomes in MJ-exposed infants compared to MJ-unexposed infants. In adjusted models, MJ-exposure was not associated with adverse neonatal outcomes (aOR 0.83 95% CI 0.47,1.44) or early childhood outcomes (aOR 1.47, 95% CI 0.97,2.23).. Among infants born <35 weeks of gestation, MJ-exposure was not associated with adverse neonatal or childhood outcomes. Long-term follow-up studies are needed to assess later childhood neurodevelopmental outcomes following MJ-exposure. Topics: Cannabis; Cerebral Palsy; Child Development; Child, Preschool; Developmental Disabilities; Female; Humans; Infant; Infant, Newborn; Infant, Premature; Infant, Premature, Diseases; Magnesium Sulfate; Male; Marijuana Abuse; Morbidity; Pregnancy; Pregnancy Complications; Prenatal Exposure Delayed Effects; Risk Factors	2017

Article

Year

Risk of neonatal and childhood morbidity among preterm infants exposed to marijuana.

The journal of maternal-fetal & neonatal medicine : the official journal of the European Association of Perinatal Medicine, the Federation of Asia and Oceania Perinatal Societies, the International Society of Perinatal Obstetricians, 2017, Volume: 30, Issue:24

Limited data exist regarding the neonatal and neurodevelopmental outcomes of infants exposed to marijuana (MJ) in-utero, particularly among preterm infants. We hypothesized that MJ-exposed preterm infants would have worse neonatal and childhood developmental outcomes compared to MJ-unexposed infants.. Secondary analysis of multicenter randomized-controlled trial of antenatal magnesium sulfate for the prevention of cerebral palsy was conducted. Singleton nonanomalous infants delivered <35 weeks exposed to MJ in-utero were compared to MJ-unexposed. Primary neonatal outcome was death, grade 3/4 intraventricular hemorrhage, periventricular leukomalacia, bronchopulmonary dysplasia, and/or stage II/III necrotizing enterocolitis before discharge. Primary childhood outcome was death, moderate/severe cerebral palsy, or/and Bayley II Scales <70 at age 2. Backward-stepwise regression used to estimate odds of primary outcomes.. 1867 infants met inclusion criteria; 135(7.2%) were MJ-exposed. There were no differences in neonatal (20% vs. 26%, p = 0.14) or childhood (26% vs. 21%, p = 0.21) outcomes in MJ-exposed infants compared to MJ-unexposed infants. In adjusted models, MJ-exposure was not associated with adverse neonatal outcomes (aOR 0.83 95% CI 0.47,1.44) or early childhood outcomes (aOR 1.47, 95% CI 0.97,2.23).. Among infants born <35 weeks of gestation, MJ-exposure was not associated with adverse neonatal or childhood outcomes. Long-term follow-up studies are needed to assess later childhood neurodevelopmental outcomes following MJ-exposure.

Topics: Cannabis; Cerebral Palsy; Child Development; Child, Preschool; Developmental Disabilities; Female; Humans; Infant; Infant, Newborn; Infant, Premature; Infant, Premature, Diseases; Magnesium Sulfate; Male; Marijuana Abuse; Morbidity; Pregnancy; Pregnancy Complications; Prenatal Exposure Delayed Effects; Risk Factors

2017

Other Studies

1 other study(ies) available for humulene and Infant--Premature--Diseases

Article	Year
NARCOTIC AND METHAMPHETAMINE USE DURING PREGNANCY. EFFECT ON NEWBORN INFANTS. American journal of diseases of children (1960), 1963, Volume: 106 Topics: Barbiturates; Cannabis; Codeine; Female; Heroin; Humans; Infant; Infant, Newborn; Infant, Newborn, Diseases; Infant, Premature, Diseases; Maternal-Fetal Exchange; Methamphetamine; Narcotics; Pregnancy; Pregnancy Complications; Substance-Related Disorders; Toxicology	1963

Article

Year

NARCOTIC AND METHAMPHETAMINE USE DURING PREGNANCY. EFFECT ON NEWBORN INFANTS.

American journal of diseases of children (1960), 1963, Volume: 106

Topics: Barbiturates; Cannabis; Codeine; Female; Heroin; Humans; Infant; Infant, Newborn; Infant, Newborn, Diseases; Infant, Premature, Diseases; Maternal-Fetal Exchange; Methamphetamine; Narcotics; Pregnancy; Pregnancy Complications; Substance-Related Disorders; Toxicology

1963